News and Announcements
John Kelly, Atomo Diagnostics’ Founder and CEO Interviewed on Switzer TV
- Published May 31, 2016 1:52PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
25th May 2016, Swtizter
Atomo Diagnostics is making waves in the diagnostics technology space, and has even attracted the support of the Bill and Melinda Gates Foundation. To look at the company’s innovations, CEO John Kelly joins the show (broadcast on Wednesday 25 May, 2016).
About Atomo Diagnostics
Atomo Diagnostics is a multi-award winning and rapidly growing medical device company that has developed and commercialised AtomoRapid™, the world’s first integrated device for blood based immunoassay rapid diagnostic testing (RDTs) in point of care settings.
Atomo launched its first test on the platform, AtomoRapid HIV, in 2014. Since launch, AtomoRapid tests have quickly established themselves as a “best in class” solution for professional use diagnostic screening.
To watch the interview, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
